Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-7.32%
-1.99%
+0.14%
-3.06%
DMAC
DiaMedica Therapeutics
$7.00
Login to see DiaMedica Therapeutics (DMAC) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Chart
$7.2 (-2.78%)
$3.63 (+92.84%)
$3.98 (+75.88%)
$4.34 (+61.29%)
DMAC has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Low volume
High volatilty
DMAC overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
DMAC Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
DMAC Street view is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayDMAC Earnings
The TTM reflects 12-month period, providing review of DMAC financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is DMAC current stock price?
What are DMAC stock strengths?
What risks are associated with DMAC stock?
When is DMAC next earnings report?
What is DMAC market cap and volume?
What is DMAC's current Stock IQ?
Should I buy DMAC stock right now?
Is DMAC a Strong Buy right now?
What does a 'Strong Buy' rating mean for DMAC?
What does a 'Strong Sell' rating mean for DMAC?
What factors influence DMAC's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.32%
-1.99%
+0.14%
-3.06%
DMAC
DiaMedica Therapeutics
Current Price
$7.00
Stock Insights
Strengths
Earnings are forecast to grow
Login to unlock DiaMedica Therapeutics (DMAC) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$7.2 (-2.78%)
$3.63 (+92.84%)
$3.98 (+75.88%)
$4.34 (+61.29%)
DMAC Analysts Opinion
DMAC Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
DMAC Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
DMAC Street view is extremely bullish and have negative views on the near-term outlook
DMAC has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Low volume
High volatilty
Average key support and resistance price levels.
Login to displayDMAC Earnings
The TTM data reflects the most recent 12-month period, providing overview of DMAC financial performance.
DMAC Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
DMAC Latest Analysis
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4). DiaMedica Therapeutics Inc. (NASDAQ: ) a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia fetal growth restriction and acute ischemic stroke today announced that on September 18 2025 it granted stock options to purchase an aggregate of 490000 shares of DiaMedica'.s common stock to five newly hired non-executive employees whose employment commenced in August and Septembe
Mon Sep 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
DMAC Stock trends
DMAC Stock performance
DMAC Stock analysis
DMAC investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings